816. Interactive Panelist
Session: Interactive Session: Approach to Clinical Syndromes in the Transplant Patient
Saturday, October 22, 2011: 9:15 AM
Room: Grand Ballroom (East-West)

Jutta Preiksaitis, MD, FRCP (C), University of Alberta, Edmonton, AB, Canada

Jutta Krista Preiksaitis, MD, FRCP
Jutta Preiksaitis is the Medical Director of the Provincial Laboratory for Public Health (Microbiology) [ProvLab Alberta] in Edmonton, Alberta and a professor of medicine in the division of infectious diseases at the University of Alberta. She has been involved in research relating to infectious disease since 1983, focusing on epidemiology, pathogenesis, and diagnosis of infections transmitted by organ transplantation and blood transfusion. Her special interests are in the laboratory surveillance of cytomegalovirus, Epstein-Barr virus, and hepatitis viruses after solid organ transplantation and blood transfusion, the diagnosis and management of EBV-associated post-transplant lymphoproliferative disorder and improving diagnosis in clinical virology in support of public health programs and transplantation. Dr. Preiksaitis’ research has been published in articles, reviews, book chapters, and abstracts and presented at international meetings.
Dr. Preiksaitis has served as chair of the infectious diseases committee of the American Society of Transplantation and provincial co-chair of the Canadian Public Health Laboratory Network. She has served on national advisory committees related to issues of xenotransplantation, organ, tissue, and blood donor safety, and hepatitis C epidemiology and diagnosis.
Dr. Preiksaitis received her medical degree from McMaster University in Hamilton, Ontario and completed her residency in internal medicine at the University of Toronto and the University of Alberta hospitals. Dr. Preiksaitis received additional training in infectious diseases and research at the Universities of Manitoba and Alberta and Stanford University.

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.